|
1.
|
Chen YX, Wang Y, Fu CC, Diao F, Song LN,
Li ZB, Yang R and Lu J: Dexamethasone enhances cell resistance to
chemotherapy by increasing adhesion to extracellular matrix in
human ovarian cancer cells. Endocr Relat Cancer. 17:39–50. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Dong Y, Tan OL, Loessner D, Stephens C,
Walpole C, Boyle GM, Parsons PG and Clements JA: Kallikrein-related
peptidase 7 promotes multicellular aggregation via the alpha(5)
beta(1) integrin pathway and paclitaxel chemoresistance in serous
epithelial ovarian carcinoma. Cancer Res. 70:2624–2633. 2010.
View Article : Google Scholar
|
|
3.
|
Loessner D, Stok KS, Lutolf MP, Hutmacher
DW, Clements JA and Rizzi SC: Bioengineered 3D platform to explore
cell-ECM interactions and drug resistance of epithelial ovarian
cancer cells. Biomaterials. 31:8494–8506. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Stumm S, Meyer A, Lindner M, Bastert G,
Wallwiener D and Gückel B: Paclitaxel treatment of breast cancer
cell lines modulates Fas/Fas ligand expression and induces
apoptosis which can be inhibited through the CD40 receptor.
Oncology. 66:101–111. 2004. View Article : Google Scholar
|
|
5.
|
Huang Y, Ibrado AM, Reed JC, Bullock G,
Ray S, Tang C and Bhalla K: Co-expression of several molecular
mechanisms of multidrug resistance and their significance for
paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia.
11:253–257. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Kamazawa S, Kigawa J, Kanamori Y, Itamochi
H, Sato S, Iba T and Terakawa N: Multidrug resistance gene-1 is a
useful predictor of Paclitaxel-based chemotherapy for patients with
ovarian cancer. Gynecol Oncol. 86:171–176. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Swanton C, Nicke B, Schuett M, Eklund AC,
Ng C, Li Q, Hardcastle T, Lee A, Roy R, East P, Kschischo M,
Endesfelder D, Wylie P, Kim SN, Chen JG, Howell M, Ried T,
Habermann JK, Auer G, Brenton JD, Szallasi Z and Downward J:
Chromosomal instability determines taxane response. Proc Natl Acad
Sci USA. 106:8671–8676. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Satyaswaroop PG, Frost A and Gurpide E:
Metabolism and effects of progesterone in the human endometrial
adenocarcinoma cell line HEC-1. Steroids. 35:21–37. 1980.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Gibas Z, Prout GR, Conolly JG, Pontes JE
and Sandberg AA: Nonrandom chromosome changes in transitional cell
carcinoma of the bladder. Cancer Res. 44:1257–1264. 1984.PubMed/NCBI
|
|
10.
|
Yoshida MA, Ohyashiki K, Ochi H, Gibas Z,
Pontes JE, Prout GR Jr, Huben R and Sandberg AA: Cytogenetic
studies of tumor tissue from patients with nonfamilial renal cell
carcinoma. Cancer Res. 46:2139–2147. 1986.PubMed/NCBI
|
|
11.
|
Yunis JJ: New chromosome techniques in the
study of human neoplasia. Hum Pathol. 12:540–549. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Tanaka T, Bai T, Yukawa K, Utsunomiya T
and Umesaki N: Reduced radiosensitivity and increased CD40
expression in cyclophosphamide-resistant subclones established from
human cervical squamous cell carcinoma cells. Oncol Rep.
14:941–948. 2005.
|
|
13.
|
Tanaka T, Bai T and Toujima S:
Establishment and characterization of monoclonal
5-fluorouracil-resistant cell lines derived from human endometrial
adenocarcinoma. Int J Oncol. 37:731–736. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Tanaka T, Toujima S and Umesaki N:
Growth-inhibitory signals by activin A do not affect anticancer
drug-sensitivity and acquired multi-drig-resistance in human
ovarian endometrioid adenocarcinoma OVK-18 cells. Oncol Rep.
11:667–671. 2004.
|
|
15.
|
Tanaka T, Bai T, Yukawa K and Umesaki N:
Optimal combination chemotherapy and chemoradiotherapy with
etoposide for advanced cervical squamous cancer cells in vitro.
Oncol Rep. 15:939–947. 2006.PubMed/NCBI
|
|
16.
|
Ohbayashi M, Yasuda M, Kawakami I, Kohyama
N, Kobayashi Y and Yamamoto T: Effect of interleukins response to
ECM-induced acquisition of drug resistance in MCF-7 cells. Exp
Oncol. 30:276–282. 2008.PubMed/NCBI
|
|
17.
|
To K, Fotovati A, Reipas KM, Law JH, Hu K,
Wang J, Astanehe A, Davies AH, Lee L, Stratford AL, Raouf A,
Johnson P, Berquin IM, Royer HD, Eaves CJ and Dunn SE: Y-box
binding protein-1 induces the expression of CD44 and CD49f leading
to enhanced self-renewal, mammosphere growth, and drug resistance.
Cancer Res. 70:2840–2851. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Işeri OD, Kars MD, Arpaci F and Gündüz U:
Gene expression analysis of drug-resistant MCF-7 cells:
implications for relation to extracellular matrix proteins. Cancer
Chemother Pharmacol. 65:447–55. 2010.PubMed/NCBI
|
|
19.
|
Lanni JS, Lowe SW, Licitra EJ, Liu JO and
Jacks T: p53-independent apoptosis induced by paclitaxel through an
indirect mechanism. Proc Natl Acad Sci USA. 94:9679–83. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Biswas RS, Cha HJ, Hardwick JM and
Srivastava RK: Inhibition of drug-induced Fas ligand transcription
and apoptosis by Bcl-XL. Mol Cell Biochem. 225:7–20. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Shivanna M and Srinivas SP: Microtubule
stabilization opposes the (TNF-alpha)-induced loss in the barrier
integrity of corneal endothelium. Exp Eye Res. 89:950–959. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Voorzanger-Rousselot N, Alberti L and Blay
JY: CD40L induces multidrug resistance to apoptosis in breast
carcinoma and lymphoma cells through caspase independent and
dependent pathways. BMC Cancer. 18:752006. View Article : Google Scholar
|
|
23.
|
Wang MY, Chen PS, Prakash E, Hsu HC, Huang
HY, Lin MT, Chang KJ and Kuo ML: Connective tissue growth factor
confers drug resistance in breast cancer through concomitant
up-regulation of Bcl-xL and cIAP1. Cancer Res. 69:3482–3491. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Luo D, Cheng SC, Xie H and Xie Y: Effects
of Bcl-2 and Bcl-XL protein levels on chemoresistance of
hepatoblastoma HepG2 cell line. Biochem Cell Biol. 78:119–126.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Janssen K, Pohlmann S, Jänicke RU,
Schulze-Osthoff K and Fischer U: Apaf-1 and caspase-9 deficiency
prevents apoptosis in a Bax-controlled pathway and promotes
clonogenic survival during paclitaxel treatment. Blood.
110:3662–3672. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Strobel T, Kraeft SK, Chen LB and
Cannistra SA: BAX expression is associated with enhanced
intracellular accumulation of paclitaxel: a novel role for BAX
during chemotherapy-induced cell death. Cancer Res. 58:4776–4781.
1998.PubMed/NCBI
|
|
27.
|
Kitazono M, Sumizawa T, Takebayashi Y,
Chen ZS, Furukawa T, Nagayama S, Tani A, Takao S, Aikou T and
Akiyama S: Multidrug resistance and the lung resistance-related
protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst.
91:1647–1653. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Tanaka T, Toujima S, Toyoda S, Takeuchi S
and Umesaki N: Establishment and characterization of novel human
uterine leiomyosarcoma cell lines. Int J Oncol. 35:125–131.
2010.PubMed/NCBI
|
